Your browser doesn't support javascript.
loading
[Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome]. / Thrombose veineuse profonde traitée par rivaroxaban chez une jeune patiente atteinte de carbohydrate-deficient glycoprotein syndrome de type Ia.
Lefrère, Bertrand; Stepanian, Alain; Itzhar-Baïkian, Nathalie; Charles, Perrine; Hadj-Ali, Arezki; Joly, Bérangère; Alhenc-Gelas, Martine; Drouet, Ludovic; Veyradier, Agnès; Siguret, Virginie.
  • Lefrère B; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Stepanian A; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Itzhar-Baïkian N; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Charles P; Département de génétique clinique, Centre de référence « Déficiences intellectuelles de causes rares ¼, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.
  • Hadj-Ali A; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Joly B; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Alhenc-Gelas M; Service d'hématologie biologique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
  • Drouet L; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Veyradier A; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
  • Siguret V; Service d'hématologie biologique, Hôpital Lariboisière, AP-HP, Paris, France.
Ann Biol Clin (Paris) ; 76(2): 217-223, 2018 04 01.
Article en Fr | MEDLINE | ID: mdl-29623892
ABSTRACT
Congenital disorders of glycosylation (CDG) are rare inborn diseases of glycan component of N-glycosylated proteins. We report here the case of a 28-year-old patient with CDG syndrome type Ia, who presented with a deep venous thrombosis in the left suro-popliteal vein with no known triggers or antecedents. The patient was treated with rivaroxaban for six months. Blood tests performed after discontinuing anticoagulant treatment showed multiple abnormalities affecting the proteins involved in haemostasis (both coagulation factors and inhibitors), i.e. a combined factor XI, antithrombin and protein C deficiency (35%, 41%, and 42% respectively) associated with a moderate increase of FVIII (179%) and VWFAg (163%) without inflammation. Patient results are here discussed with regard to the limited number of articles addressing haemostasis in this rare disease, as the occurrence of deep venous thrombosis remains uncommon in the literature.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fosfotransferasas (Fosfomutasas) / Trastornos Congénitos de Glicosilación / Trombosis de la Vena / Rivaroxabán Límite: Adult / Female / Humans Idioma: Fr Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fosfotransferasas (Fosfomutasas) / Trastornos Congénitos de Glicosilación / Trombosis de la Vena / Rivaroxabán Límite: Adult / Female / Humans Idioma: Fr Año: 2018 Tipo del documento: Article